Medine.co.uk

Rispoval 4

Revised: December 2015

AN: 00648/2015

SUMMARY OF PRODUCT CHARACTERISTICS


NAME OF THE VETERINARY MEDICINAL PRODUCT


Rispoval 4


QUALITATIVE AND QUANTITATIVE COMPOSITION


Each 5 ml dose contains:

Suspension fraction:


* GMT Serological titre induced after injection to calves.


Lyophilisate fraction:


Adjuvant:

Aluminium hydroxide (2 % Al2O3) ≤ 5.2 mg Al203per ml


For a full list of excipients, see Section 6.1.


PHARMACEUTICAL FORM


Lyophilisate for suspension in diluent.

CLINICAL PARTICULARS


Target Species


Cattle


Indications for Use, Specifying the Target Species


For active immunisation of cattle to reduce infection, clinical signs and respiratory disease caused by Bovine Respiratory Syncytial virus (BRSV), Infectious Bovine Rhinotracheitis (IBR, commonly known as BHV-1) virus and Parainfluenza virus type 3 (PI3); and leucopaenia and viraemia caused by the Bovine Viral Diarrhoea virus (BVDV) Type I, cytopathic and non-cytopathic strains. A duration of immunity of at least 6 months has been demonstrated.


Contraindications


None


Special warnings for Cattle


None.


Special precautions for use


Special precautions for use in animals


None.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


None


Adverse reactions (frequency and seriousness)


Very occasionally, administration of the vaccine may be followed by a mild transient reaction at the injection site up to 0.5 cm and completely resolved within 15 days.


Use during pregnancy, lactation or lay


Do not use during pregnancy.


Interaction with other medicinal products and other forms of interaction


No information is available on the safety and efficacy from the concurrent use of this vaccine with any other product except Rispoval™ Pasteurella. Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.


Amounts to be administered and administration route


Reconstitute the vaccine by mixing the lyophilised fraction with the suspension in 2 steps:

1. Inject 10ml of the liquid fraction on the lyophilised plug in the freeze dried vial.

2. Shake well and extract the reconstituted lyophilised fraction from the freeze dried vial and mix with the liquid fraction in the liquid fraction vial.

Shake well before use.


Vaccination programme:

For cattle over 3 months of age:

Two doses of 5ml of reconstituted vaccine should be given three to four weeks apart to cattle over the age of 3 months, via the intramuscular route.


Ideally, calves should be vaccinated at least 2 weeks before transport, mixing of animals of different origins, housing, or any other event which may cause the animals to be stressed or exposed to new infections. Calves are usually most susceptible during early autumn. The vaccine will protect animals against BRSV, PI3, IBR and BVD for at least 6 months, which will cover the period of risk from respiratory infections.


Should cattle be at risk from these respiratory diseases at a subsequent time, the same vaccination scheme is recommended at least 14 days prior to the period of expected disease challenge.


For cattle over 3 weeks of age:

For cattle from 3 weeks of age, vaccination leads to seroconversion of seronegative calves vaccinated at 3 and 6 weeks of age. The influence of maternally derived antibodies has not been studied in detail and it is therefore recommended that calves vaccinated before 12 weeks of age are re-vaccinated at 12 weeks of age.


Overdose (symptoms, emergency procedures, antidotes), if necessary


No symptoms other than those mentioned in Section 4.6.


Withdrawal Period


Zero days


IMMUNOLOGICAL PROPERTIES


ATCVet code:QI02AH

To stimulate active immunity against BRSV, PI3, IBR (BHV-1) and cytopathic and non-cytopathic strains of BVD Type I viruses in cattle.


PHARMACEUTICAL PARTICULARS


List of excipients


Aluminium hydroxide.


Incompatibilities


Do not mix with any other vaccine/immunological product.



Shelf-life


Shelf life of the veterinary medicinal product as packaged for sale: 2 years (lyophilisate).

Shelf life of the veterinary medicinal product as packaged for sale: 3 years (suspension)

Reconstituted vaccine should be used within 2 hours.


Special Precautions for Storage


Store and transport away from light and between + 2°C and + 8°C. Do not freeze.


Nature and composition of immediate packaging


Cardboard box with 1 glass vial containing 5 doses of lyophilisate accompanied by 1 glass vial containing 5 doses (25 ml) of suspension.


Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products, if appropriate


Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.


MARKETING AUTHORISATION HOLDER


Zoetis UK Limited

5th Floor, 6 St. Andrew Street

London

EC4A 3AE


MARKETING AUTHORISATION NUMBER


Vm 42058/4125


DATE OF THE FIRST AUTHORISATION


31 May 2001


DATE OF REVISION OF THE TEXT


December 2015



22 December 2015

Page 4 of 4